Total Payments
$770,178
2024 Payments
$97,043
Companies
21
Transactions
574
Medicare Patients
733
Medicare Billing
$195,780
Payment Breakdown by Category
Other$455,164 (59.1%)
Consulting$174,723 (22.7%)
Travel$86,020 (11.2%)
Research$42,019 (5.5%)
Food & Beverage$12,136 (1.6%)
Education$115.72 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $446,874 | 133 | 58.0% |
| Consulting Fee | $174,723 | 74 | 22.7% |
| Travel and Lodging | $86,020 | 165 | 11.2% |
| Unspecified | $42,019 | 32 | 5.5% |
| Food and Beverage | $12,136 | 161 | 1.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,900 | 1 | 0.6% |
| Honoraria | $3,390 | 2 | 0.4% |
| Education | $115.72 | 6 | 0.0% |
Payments by Type
General
$728,159
542 transactions
Research
$42,019
32 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $164,735 | 109 | $0 (2024) |
| PFIZER INC. | $140,835 | 99 | $0 (2024) |
| Seagen Inc. | $105,327 | 76 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $89,585 | 72 | $0 (2024) |
| Genentech USA, Inc. | $81,943 | 60 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $48,608 | 37 | $0 (2024) |
| Stemline Therapeutics Inc. | $46,956 | 34 | $0 (2024) |
| Daiichi Sankyo Inc. | $46,752 | 29 | $0 (2024) |
| Puma Biotechnology, Inc. | $24,213 | 29 | $0 (2022) |
| JAZZ PHARMACEUTICALS INC. | $12,207 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $97,043 | 69 | Gilead Sciences, Inc. ($36,701) |
| 2023 | $166,954 | 106 | Gilead Sciences, Inc. ($55,338) |
| 2022 | $156,146 | 105 | Gilead Sciences, Inc. ($52,226) |
| 2021 | $91,877 | 61 | Seagen Inc. ($26,177) |
| 2020 | $40,445 | 30 | Seagen Inc. ($19,404) |
| 2019 | $83,449 | 81 | Genentech USA, Inc. ($34,767) |
| 2018 | $69,854 | 70 | Genentech USA, Inc. ($25,380) |
| 2017 | $64,410 | 52 | PFIZER INC. ($24,845) |
All Payment Transactions
574 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,010.00 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $70.26 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Genentech USA, Inc. | Itovebi (Biological) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: BioOncology | ||||||
| 12/10/2024 | Genentech USA, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $228.46 | General |
| Category: BioOncology | ||||||
| 12/10/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $71.16 | General |
| Category: Oncology | ||||||
| 12/05/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $8.09 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,900.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,950.00 | General |
| Category: ONC | ||||||
| 11/12/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/22/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| Category: ONC | ||||||
| 10/07/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,480.00 | General |
| Category: Oncology | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,280.00 | General |
| 09/20/2024 | JAZZ PHARMACEUTICALS INC. | — | Consulting Fee | Cash or cash equivalent | $8,580.00 | General |
| 09/20/2024 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | In-kind items and services | $171.54 | General |
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $123.36 | General |
| 09/16/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $122.01 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,860.00 | General |
| Category: Oncology | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Travel and Lodging | In-kind items and services | $446.53 | General |
| Category: Oncology | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $118.89 | General |
| Category: Oncology | ||||||
| 09/02/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $342.50 | General |
| 08/23/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| Category: ONC | ||||||
| 08/16/2024 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $74.99 | General |
| 08/16/2024 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $49.99 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $17,840 | 16 |
| Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat | Novartis Pharmaceuticals Corporation | $7,175 | 1 |
| IBRANCE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,784 | 3 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,832 | 3 |
| CLEE011O12301C | Novartis Pharmaceuticals Corporation | $2,540 | 1 |
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,900 | 1 |
| CLEE011A2301,CLEE011E2301,CLEE011F2301 | Novartis Pharmaceuticals Corporation | $939.31 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH PIQRAY RESEARCH | Novartis Pharmaceuticals Corporation | $713.00 | 1 |
| A phase I II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER breast cancer | GlaxoSmithKline, LLC. | $104.57 | 1 |
| A PHASE I-II DOSE ESCALATION AND EXPANSION STUDY TO INVESTIGATE THE SA | GlaxoSmithKline, LLC. | $67.93 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 98 | 414 | $93,910 | $32,803 |
| 2022 | 7 | 259 | 814 | $174,652 | $59,867 |
| 2021 | 6 | 201 | 751 | $158,512 | $56,613 |
| 2020 | 3 | 175 | 788 | $159,375 | $46,497 |
Total Patients
733
Total Services
2,767
Medicare Billing
$195,780
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 57 | 293 | $60,651 | $20,717 | 34.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 30 | 106 | $30,634 | $11,519 | 37.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 15 | $2,625 | $566.28 | 21.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 110 | 613 | $126,891 | $43,722 | 34.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 48 | 79 | $22,831 | $8,100 | 35.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 44 | 50 | $8,750 | $2,426 | 27.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 21 | 21 | $4,305 | $1,658 | 38.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $5,525 | $1,497 | 27.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 24 | $3,480 | $1,341 | 38.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 14 | $2,870 | $1,123 | 39.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 83 | 576 | $116,901 | $42,258 | 36.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 39 | 70 | $19,816 | $7,354 | 37.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 38 | 57 | $9,975 | $2,572 | 25.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $6,375 | $2,293 | 36.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 22 | $3,190 | $1,255 | 39.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 11 | 11 | $2,255 | $881.65 | 39.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 87 | 670 | $134,000 | $39,883 | 29.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 33 | 45 | $12,600 | $4,029 | 32.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 55 | 73 | $12,775 | $2,585 | 20.2% |
About Dr. Timothy Pluard, MD
Dr. Timothy Pluard, MD is a Medical Oncology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396761698.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Timothy Pluard, MD has received a total of $770,178 in payments from pharmaceutical and medical device companies, with $97,043 received in 2024. These payments were reported across 574 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($446,874).
As a Medicare-enrolled provider, Pluard has provided services to 733 Medicare beneficiaries, totaling 2,767 services with total Medicare billing of $195,780. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Kansas City, MO
- Active Since 07/14/2006
- Last Updated 10/24/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1396761698
Products in Payments
- Trodelvy (Drug) $163,403
- TUKYSA (Drug) $110,163
- IBRANCE (Drug) $93,108
- KISQALI (Drug) $51,967
- Orserdu (Drug) $46,956
- Perjeta (Biological) $42,872
- PIQRAY (Drug) $27,920
- ENHERTU (Drug) $27,510
- TALZENNA (Drug) $26,312
- Nerlynx (Drug) $24,144
- Herceptin (Biological) $18,068
- ENHERTU (Biological) $16,563
- Enhertu (Drug) $15,837
- LYNPARZA (Drug) $11,871
- Kadcyla (Biological) $10,882
- TECENTRIQ (Biological) $5,122
- BYL719 (Drug) $3,076
- Phesgo (Biological) $2,895
- Itovebi (Biological) $2,103
- Truqap (Drug) $2,055
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Kansas City
Dr. Amandeep Kalra, M.d, M.D
Medical Oncology — Payments: $22,301
Medical Oncology $22,301
David Bouda, Md, MD
Medical Oncology — Payments: $6,727
Medical Oncology $6,727
Mrs. Shajadi Patan, M.d, M.D
Medical Oncology — Payments: $6,158
Medical Oncology $6,158
Sreekanth Donepudi, Md , Mph, MD , MPH
Medical Oncology — Payments: $3,761
Medical Oncology $3,761
Dr. Allan Fleming, M.d, M.D
Medical Oncology — Payments: $19.81
Medical Oncology $19.81